Loading…
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-180M | $-158M | $-132M | -57.5% | - | - |
| 2024 | $0M | $-193M | $-168M | $-135M | -38.4% | - | - |
| 2023 | $0M | $-164M | $-136M | $-85M | -24.5% | - | - |
| 2022 | $0M | $-130M | $-116M | $-123M | -18.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 130.65 | 164.16 | 192.95 | 180.89 |
| Operating Income | -130.65 | -164.16 | -192.95 | -180.89 |
| EBITDA | -130.39 | -163.75 | -192.53 | -180.47 |
| EBIT | -130.65 | -164.16 | -192.95 | -180.89 |
| Pretax Income | -119.50 | -134.94 | -167.46 | -164.51 |
| Tax Provision | -3.59 | 1.02 | 0.93 | -6.16 |
| Net Income | -115.91 | -135.96 | -168.38 | -158.35 |
| Net Income Common Stockholders | -115.91 | -135.96 | -168.38 | -158.35 |
| Total Expenses | 130.65 | 164.16 | 192.95 | 180.89 |
| Interest Income | 11.15 | 29.22 | 25.49 | 16.38 |
| Research And Development | 81.94 | 114.24 | 144.10 | 148.02 |
| Selling General And Administration | 48.71 | 49.92 | 48.85 | 32.86 |
| Normalized EBITDA | -130.39 | -163.75 | -192.53 | -180.47 |
| Normalized Income | -115.91 | -135.96 | -168.38 | -158.35 |
| Basic EPS | -1.39 | -1.63 | -2 | 0 |
| Diluted EPS | -1.39 | -1.63 | -2 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.03 | 0.21 | 0.21 | 0.04 |
| Net Income From Continuing Operation Net Minority Interest | -115.91 | -135.96 | -168.38 | -158.35 |
| Reconciled Depreciation | 0.26 | 0.42 | 0.42 | 0.42 |
| Net Interest Income | 11.15 | 29.22 | 25.49 | 16.38 |
| Net Income From Continuing And Discontinued Operation | -115.91 | -135.96 | -168.38 | -158.35 |
| Total Operating Income As Reported | -130.65 | -164.16 | -192.95 | -180.89 |
| Diluted Average Shares | 83.25 | 83.39 | 84.26 | 0 |
| Basic Average Shares | 83.25 | 83.39 | 84.26 | 0 |
| Diluted NI Availto Com Stockholders | -115.91 | -135.96 | -168.38 | -158.35 |
| Net Income Including Noncontrolling Interests | -115.91 | -135.96 | -168.38 | -158.35 |
| Net Income Continuous Operations | -115.91 | -135.96 | -168.38 | -158.35 |
| Net Non Operating Interest Income Expense | 11.15 | 29.22 | 25.49 | 16.38 |
| Interest Income Non Operating | 11.15 | 29.22 | 25.49 | 16.38 |
| General And Administrative Expense | 48.71 | 49.92 | 48.85 | 32.86 |
| Other Gand A | 48.71 | 49.92 | 48.85 | 32.86 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc.this co. | AVIR | $435M | - | 1.54 | -57.5% | -0.73 |
| Myriad Genetics, Inc. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| REGENXBIO Inc. | RGNX | $434M | - |
| 4.16 |
| -188.7% |
| -3.19 |
| Evolent Health, Inc. | EVH | $432M | - | 1.02 | -128.7% | 14.29 |
| Aura Biosciences, Inc. | AURA | $432M | - | 3.13 | -77.6% | -2.73 |
| Fulgent Genetics, Inc. | FLGT | $427M | - | 0.41 | -5.5% | -1.98 |
| Vanda Pharmaceuticals Inc. | VNDA | $424M | - | 1.27 | -67.4% | -1.16 |
| Peer Median | - | - | 1.45 | -72.5% | -2.65 | |